Neptune to Hold Conference Call
2012年5月30日 - 11:35PM
Neptune Technologies and Bioressources Inc. (Nasdaq:NEPT) (TSX:NTB)
will be holding a conference call and webcast on Thursday May 31,
2012 at 4:30 pm ET.
Main topics to be discussed on the call include:
- Year End financial results,
- Commercial progress,
- Plant expansion,
- Intellectual property,
- NeuroBioPharm Update,
- Acasti Pharma Update.
Conference call hosts:
- Henri Harland, President & CEO
- André Godin, CFO
- Benoit Huart, Director of Legal Affairs
The webcast can be accessed in listen only mode, free of charge,
by clicking the link below:
http://investor.shareholder.com/media/eventdetail.cfm?eventid=114557&CompanyID=ABEA-2FTYUQ&e=2&mediaKey=00C91657CB563BC69C078A021724CDA6
To access the conference call by phone within Canada and the
U.S. the toll-free number is
1-877-380-5664.
Outside Canada and the U.S., dial
1-631-813-4882.
Conference call details:
Conference Topic: Neptune Technologies & Bioressources:
Corporate Update
Conference ID: 86582975
Management will accept questions by telephone during the Q&A
period at the end of the presentation. Questions can also be
forwarded in advance or during the presentation to
f.harland@neptunebiotech.com.
An archived recording of the webcast will be available on
Neptune's website (www.neptunebiotech.com) two hours after the
webcast.
About Neptune Technologies & Bioressources
Inc.
Neptune is an industry-recognized leader in the innovation,
production and formulation of science-based and clinically proven
novel phospholipid products for the nutraceutical and
pharmaceutical markets. The Company focuses on growing consumer
health markets including cardiovascular, inflammatory and
neurological diseases driven by consumers taking a more proactive
approach to managing health and preventing disease. The Company
sponsors clinical trials aimed to demonstrate its product health
benefits and to obtain regulatory approval for label health claims.
Neptune is continuously expanding its intellectual property
portfolio as well as clinical studies and regulatory approvals.
Neptune's products are marketed and distributed in over 30
countries worldwide.
About Acasti Pharma Inc.
Acasti Pharma (TSXV:APO.V) is developing a product portfolio of
proprietary novel long-chain omega-3 phospholipids. Phospholipids
are the major component of cell membranes and are essential for all
vital cell processes. They are one of the principal constituents of
High Density Lipoprotein (good cholesterol) and, as such, play an
important role in modulating cholesterol efflux. Acasti Pharma's
proprietary novel phospholipids carry and functionalize the
polyunsaturated omega-3 fatty acids EPA and DHA, which have been
shown to have substantial health benefits and which are stabilized
by astaxanthin, a potent antioxidant. Acasti Pharma is focusing
initially on treatments for chronic cardiovascular and
cardiometabolic conditions within the over-the-counter, medical
food and prescription drug markets.
About NeuroBioPharm Inc.
NeuroBioPharm is pursuing pharmaceutical neurological
applications, and a clinical study for a medical food product with
a multinational partner is already initiated. The development of a
prescription drug candidate is currently in progress. Advanced
clinical development and commercialization is planned to be carried
out with multinational partners.
"Neither NASDAQ nor the TSX nor its Regulation
Services Provider (as that term is defined in the policies of the
TSX) accepts responsibility for the adequacy or accuracy of this
release."
Statements in this press release that are not statements of
historical or current fact constitute "forward-looking statements"
within the meaning of the U.S. Private Securities Litigation Reform
Act of 1995 and Canadian securities laws. Such forward-looking
statements involve known and unknown risks, uncertainties, and
other unknown factors that could cause the actual results of the
Company to be materially different from historical results or from
any future results expressed or implied by such forward-looking
statements. In addition to statements which explicitly describe
such risks and uncertainties, readers are urged to consider
statements labeled with the terms "believes," "belief," "expects,"
"intends," "anticipates," "will," or "plans" to be uncertain and
forward-looking. The forward-looking statements contained herein
are also subject generally to other risks and uncertainties that
are described from time to time in the Company's reports filed with
the Securities and Exchange Commission and the Canadian securities
commissions.
CONTACT: Neptune Contact:
Neptune Technologies & Bioressources Inc.
Andre Godin, CFO
+1.450.687.2262
a.godin@neptunebiotech.com
www.neptunebiotech.com
Howard Group Contact:
Dave Burwell
(888) 221-0915
dave@howardgroupinc.com
www.howardgroupinc.com
Neptune Wellness Solutions (NASDAQ:NEPT)
過去 株価チャート
から 6 2024 まで 7 2024
Neptune Wellness Solutions (NASDAQ:NEPT)
過去 株価チャート
から 7 2023 まで 7 2024